Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Colin F. Spraggs"'
Autor:
Lini N. Pandite, Neil Kaplowitz, Thomas Powles, Andreas du Bois, Hiroomi Tada, Matthew R. Nelson, Colin F. Spraggs, Ionel Mitrica, Linda P. Briley, Sandy Stinnett, Dana J. Fraser, Karen S. King, Zhengyu Xue, Liling Warren, Alan P. Graves, Chris Carpenter, Xiaojing Wang, Toby Johnson, Chun-Fang Xu
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib-treated patients. We conducted pharmacogenetic analyses to explore mechanistic in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3839491b219ef58d50509358882ee7ba
https://doi.org/10.1158/1078-0432.c.6524039.v1
https://doi.org/10.1158/1078-0432.c.6524039.v1
Autor:
Lini N. Pandite, Neil Kaplowitz, Thomas Powles, Andreas du Bois, Hiroomi Tada, Matthew R. Nelson, Colin F. Spraggs, Ionel Mitrica, Linda P. Briley, Sandy Stinnett, Dana J. Fraser, Karen S. King, Zhengyu Xue, Liling Warren, Alan P. Graves, Chris Carpenter, Xiaojing Wang, Toby Johnson, Chun-Fang Xu
Supplementary Table S1. Summary of eight pazopanib (monotherapy) clinical studies included in the discovery pharmacogenetic liver toxicity analysis Supplementary Table S2. Summary of 23 pazopanib clinical studies included in the confirmatory pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84251c105feab3d723a3f5866015ff3d
https://doi.org/10.1158/1078-0432.22458767
https://doi.org/10.1158/1078-0432.22458767
Autor:
Julie R. Gralow, Ajay O. Mehta, L. P. Briley, Lyndsay Harris, L. Warren, E. A. Perez, Georgia Demetriou, Julie Byrne, Masakazu Toi, Colin F. Spraggs, Martine Piccart, JoAnne Zujewski, Zeba Aziz, A Armour, S. Ahmed, Martin Andersson, Laura R. Parham, L. S. Williams, Z-f Jiang, N. Jackson, R. Crescenzo, D. J. Fraser
Publikováno v:
The Pharmacogenomics Journal. 18:480-486
HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130dedd979d5def9101526c0373bb0b0
https://doi.org/10.1038/tpj.2017.39
https://doi.org/10.1038/tpj.2017.39
Autor:
Jeff Legos, Bijoyesh Mookerjee, Kijoung Song, Colin F. Spraggs, Diptee A. Kulkarni, Linda Briley, Christine Dabrowski, Karen S. King
Publikováno v:
Pharmacogenomics. 17:459-462
Aim: Pyrexia is a common adverse event (AE) on dabrafenib treatment (monotherapy or combination with trametinib). Since germline SNPs and HLA alleles are implicated in drug-induced AEs, this study investigated their association with pyrexia. Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab79cc34c1a58f26d085d9df2c8ff322
https://doi.org/10.2217/pgs.16.4
https://doi.org/10.2217/pgs.16.4
Autor:
Linda P. Briley, Lini Pandite, Dana Fraser, Karen S. King, Xiaojing Wang, Sandy Stinnett, Colin F Spraggs, Alan P. Graves, Andreas du Bois, Hiroomi Tada, Ionel Mitrica, Matthew R. Nelson, Neil Kaplowitz, Zhengyu Xue, Thomas Powles, Liling Warren, Christopher L. Carpenter, Toby Johnson, Chun-Fang Xu
Publikováno v:
Clin Cancer Res
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib-treated patients. We conducted pharmacogenetic analyses to explore mechanistic in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::026885dfef2301a70e7c15b33654b646
https://doi.org/10.1158/1078-0432.ccr-15-2044
https://doi.org/10.1158/1078-0432.ccr-15-2044
Autor:
Karen S. King, Colin F. Spraggs, Paul J. Newcombe, Gil McVean, Zamin Iqbal, A J Slater, Matthew R. Nelson, Alexander T. Dilthey, Judong Shen, Linda P. Briley, Li Li, Charles J. Cox, Laura R. Parham
Publikováno v:
The Pharmacogenomics Journal
Lapatinib is associated with a low incidence of serious liver injury. Previous investigations have identified and confirmed the Class II allele HLA-DRB1*07:01 to be strongly associated with lapatinib-induced liver injury; however, the moderate positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c19e7272bb49a7097dcfcbb9488cb98d
https://doi.org/10.1038/tpj.2015.40
https://doi.org/10.1038/tpj.2015.40
Publikováno v:
CHEMICAL RESEARCH IN TOXICOLOGY
It is hypothesized that lapatinib-induced liver injury is caused by HLA-mediated antigen presentation to CD4 positive T cells. However, analysis of PBMC and cloned T-cells from patients with HLA-DRB1*07:01-restricted lapatinib-induced liver injury re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1ce5c428e0de8eb9beccdedbf7d930f
https://doi.org/10.1021/acs.chemrestox.6b00400
https://doi.org/10.1021/acs.chemrestox.6b00400
Autor:
Shannon K. McDonnell, Joan Curran, Dianne M. Finkelstein, Lon R. Cardon, Charles J. Cox, E. Rappold, Laura R. Parham, Bent Ejlertsen, Daniel J. Schaid, Colin F. Spraggs, Paul E. Goss
Publikováno v:
Journal of Clinical Oncology. 32:2296-2303
Purpose Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously associated major histocompatibility complex (MHC) variants as predictors of risk of liver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a32afaf04b1dab0423868dffed18fbb9
https://doi.org/10.1200/jco.2013.52.9867
https://doi.org/10.1200/jco.2013.52.9867
Autor:
Linda P. Briley, Laura R. Parham, Paul E. Goss, Karen S. King, E. Rappold, Julie Byrne, Colin F. Spraggs
Publikováno v:
Pharmacogenomics. 16:1227-1229
Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous reactions, this study investigated the association of HLA alleles with lapatinib-induced rash. 11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f8f6d9a23e4a3168831202305c97ec
https://doi.org/10.2217/pgs.15.69
https://doi.org/10.2217/pgs.15.69
Autor:
A. du Bois, Laura R. Parham, L. P. Briley, Mark W. Russo, Colin F. Spraggs, Toby Johnson, Kijoung Song, Chun-Fang Xu, Hiroomi Tada
Publikováno v:
Annals of Oncology. 26:1515-1517
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d733588c28ef7780bd2a7cf405f60f
https://doi.org/10.1093/annonc/mdv211
https://doi.org/10.1093/annonc/mdv211